macular degeneration
FDA Approves Interchangeable Biosimilars to Eylea
The FDA approved Yesafili and Opuviz as interchangeable biosimilars to Eylea to treat macular degeneration and ...
MAY 23, 2024
FDA Approves Byooviz Biosimilar for nAMD, Other Eye Conditions
The first biosimilar for an ophthalmology product, Byooviz is indicated for neovascular age-related macular ...
SEPTEMBER 21, 2021
Load more